Ideas to Innovation Clarivate

In this concluding episode of Season 3 of "Ideas to Innovation," we reflect on our journey through the episodes published in 2024 that highlight the conversations we’ve enjoyed with some of the brightest minds in education, healthcare and intellectual property law.  

 

In episode 6 in February, we explored America's literacy challenge with documentary filmmaker Jenny Mackenzie. Jenny shared her personal connection to literacy and discussed the innovative strategies being used to promote reading rights across the United States. Her insights into reading proficiency and educational reform were both eye-opening and inspiring.  

 

March brought us a conversation with Renée Aguiar-Lucander, CEO of Calliditas Therapeutics, in episode 7, who detailed the groundbreaking journey of Tarpeyo, a drug that promises to revolutionize the treatment of kidney disease. Renée explained the innovative path to FDA approval, setting new benchmarks in the pharmaceutical industry.  

 

We delved into the impact of artificial intelligence on intellectual property law in episode 8 in April, with Jay Myers from Seyfarth Shaw and Arun Hill from Clarivate. They provided valuable insights into how AI is transforming trademark searches, infringement monitoring and strategic brand decisions while addressing the ethical challenges that come with these advancements.  

 

As we wrap up Season 3, we hope the episodes have informed, inspired, and entertained you. You can also listen to the Season 3 episodes from 2023 – our end-of-year episode summarizes the five stories we shared between September and December.   

 

"Ideas to Innovation" will return later this year with more stories that showcase the power of human intellect and innovation.  

 

Stay curious, and thank you for listening.  

In this episode of Ideas to Innovation, we delve into the transformative influence of artificial intelligence (AI) on intellectual property (IP) and trademark law. Our conversation with guests Jay Myers, Director of Innovation for the Intellectual Property Practice Group at the Seyfarth Shaw international law firm, and Arun Hill, Senior Consultant, The Clarivate Center for IP and Innovation Research, unravels the complexities of integrating AI into legal practices.  

Our discussion illuminates AI's capacity to streamline trademark searches, enhance infringement monitoring, and inform strategic brand decisions. Yet, it also confronts the ethical dilemmas and practical challenges that accompany AI's rise in the legal domain.   

As we peer into the near future, our guests speculate on an era marked by increased efficiency and higher-quality decision-making in IP law, driven by AI's augmentation of human expertise. This vision underscores the importance of balancing technological advancements with the indispensable elements of human judgment and ethical considerations.  

This episode offers invaluable insights into how organizations can leverage AI to navigate the complexities of IP law, striking a balance between innovation and the critical human element of legal expertise.  

Join us to explore how AI is not only automating tasks but also augmenting the capabilities of IP professionals to achieve higher-quality outcomes for their clients.  

The remarkable journey of Calliditas Therapeutics and its groundbreaking drug, Tarpeyo, sheds light on the company’s innovative strategies and relentless pursuit of excellence that led to the successful approval of Tarpeyo by the U.S. Food and Drug Administration (FDA) for the treatment of a specific kidney disease. Our guest in this episode, Renée Aguiar-Lucander, CEO of Calliditas Therapeutics, reveals how their pioneering approach to drug development has set a new benchmark in the pharmaceutical industry. 
We explore how Calliditas Therapeutics' groundbreaking work in securing FDA approval not only marks a significant milestone for the company but also inspires a new wave of innovation in the treatment of kidney diseases. Discover the power of pioneering drug development and the bright future it heralds for patients worldwide. 
This episode also features insights from Mike Ward, Global Head of Life Sciences and Healthcare Thought Leadership at Clarivate, highlighting the importance of the Drugs to Watch 2024 report and the potential of Tarpeyo – one of 13 drugs to watch included in the report – to significantly improve patient outcomes. 
Discover a story of resilience, innovation, and success behind Tarpeyo's journey to the American market, and the broader implications for the pharmaceutical industry's approach to drug development and regulatory approval. 

Season 03 Episode 06: Reading Rights: America's Literacy Challenge with Jenny Mackenzie

Over the past year, the Ideas to Innovation podcast from Clarivate took listeners on a special journey through a world where curiosity meets ingenuity. In each of 15 episodes published in 2023, we told stories of people thinking forward in the real world, highlighting those who not only dared to dream but also transformed their dreams into reality. Our conversations with experts weren’t just talks; they were narratives of change, powerful examples of how fresh insights are solving some of the world’s most complex challenges.  

For this “Best of 2023” episode, we showcase three compelling stories, each of which serves a testament to the spirit of innovation. You’ll first hear from an associate professor who is known as a ‘scientific sleuth’ for his uncanny ability to identify falsified data in published academic research. Next, two guests share their stories about a rare hereditary disease, its devastating impacts and the role and work of scientific research in finding answers. In our final segment, an accomplished scientist, engineer, and innovator with 77 patents to her name talks about her work in breaking down complex problems, her most surprising discovery, and finding solutions that stick. We hope you enjoy this recap and continue joining us as we traverse a landscape rich in creativity and innovation, meeting extraordinary minds and witnessing their groundbreaking work in real time. 

Rapid advancements in technology and science are shaping a new era, with artificial intelligence and synthetic biology, or “syn-bio,” at the forefront. Heralded as the next big leap in science, syn-bio involves redesigning organisms for useful purposes by engineering them to have new abilities. The importance of syn-bio for people and our planet cannot be overstated. It offers novel ways of producing almost anything that human beings consume, from flavors and fabrics to foods and fuels. Today, the combination of syn-bio and AI – two of the most potent realms of science and technology – promises to unravel solutions to our most pressing challenges, including Earth’s food and water, the environment and sustainability, bioenergy, and human health care. 

One widely recognized trailblazer in syn-bio is Jim Collins, professor of medical engineering and science and professor of biological engineering at MIT. He is also a core founding faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University. In the latest episode of the “Ideas to Innovation Season 3” podcast from Clarivate, Collins helps listeners navigate through the exciting but complex landscape of syn-bio. He also discusses what it was like to be named a Citation Laureate 2023 for his pioneering work in synthetic gene circuits, which launched the field of syn-bio. Each year since 2002, the Citation Laureates program from Clarivate recognizes a small group of highly cited scientists and economists whose influence is comparable to that of past and future Nobel Prize winners.